APAC case studies

In 2023, a leading China-based biotech firm partnered with ICON to launch a global programme for a key asset. Building on a six-year strategic alliance and success in China, the client expanded into the US and Europe, prioritizing efficiency and cost control. ICON deployed a blended model—FSP in China and the US, and full-service support in Europe — to align with regional needs and strategic goals.

In July 2024, a global biopharma client partnered with ICON to expand functional support. Starting with Clinical Operations and TMF roles, the partnership grew to over 60 FTEs and now includes Clinical Quality, Systems Experts, and Late Phase, with further expansion underway.

A small Asia-based biotech engaged ICON to manage its EU orphan drug designation submission for a treatment targeting Dercum’s disease. The designation was key to supporting a planned Phase 3 study and expanding into the EU, where the company had no existing presence.

This case study shows the effectiveness of this agile and forward-thinking approach to workforce scaling under time-
sensitive conditions.

An Asia Pacific based biotech was developing a therapeutic treatment for a neurodegenerative disorder. ICON Regulatory Consulting was engaged to support market entry.

The sponsor sought out ICON’s data management resources for their support in several international and complex programs using our FSP model across several therapeutic areas: oncology, neurology, infectious disease, endocrinology, and nephrology.

A China-based biotech required an FSP model to grow team to 130 resources and increase retention to 85% in a highly competitive market.

A Chinese sponsor adopts a blended delivery model to realise cost savings and assume greater autonomy.